 Ivor Douglas
Concepts (598)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiration, Artificial | 24 | 2025 | 594 | 3.920 |
Why?
| | Sepsis | 20 | 2025 | 556 | 2.920 |
Why?
| | Fluid Therapy | 12 | 2025 | 135 | 2.530 |
Why?
| | Respiratory Insufficiency | 12 | 2023 | 311 | 2.370 |
Why?
| | Critical Care | 19 | 2025 | 544 | 2.310 |
Why?
| | Critical Illness | 20 | 2025 | 729 | 2.160 |
Why?
| | Intensive Care Units | 24 | 2025 | 718 | 2.120 |
Why?
| | Tracheostomy | 5 | 2024 | 119 | 1.790 |
Why?
| | Shock, Septic | 11 | 2024 | 206 | 1.610 |
Why?
| | Hospital Mortality | 19 | 2024 | 844 | 1.550 |
Why?
| | Shock | 3 | 2024 | 95 | 1.470 |
Why?
| | Hospitals | 6 | 2023 | 631 | 1.310 |
Why?
| | Hypotension | 5 | 2025 | 114 | 1.270 |
Why?
| | Pneumonia | 7 | 2023 | 599 | 1.170 |
Why?
| | Resuscitation Orders | 3 | 2023 | 46 | 1.030 |
Why?
| | Resuscitation | 9 | 2025 | 240 | 0.990 |
Why?
| | Multiple Organ Failure | 4 | 2024 | 121 | 0.990 |
Why?
| | Humans | 135 | 2025 | 128524 | 0.890 |
Why?
| | Patient Readmission | 6 | 2021 | 664 | 0.890 |
Why?
| | Vasoconstrictor Agents | 5 | 2023 | 128 | 0.870 |
Why?
| | Ultrasonography, Doppler | 1 | 2024 | 119 | 0.850 |
Why?
| | Middle Aged | 58 | 2025 | 30893 | 0.830 |
Why?
| | Pneumonia, Ventilator-Associated | 2 | 2015 | 46 | 0.820 |
Why?
| | Aged | 45 | 2025 | 21971 | 0.820 |
Why?
| | Safety-net Providers | 3 | 2023 | 109 | 0.760 |
Why?
| | Hospitals, High-Volume | 2 | 2019 | 39 | 0.760 |
Why?
| | Hemodynamics | 3 | 2024 | 1083 | 0.740 |
Why?
| | Severity of Illness Index | 6 | 2021 | 2736 | 0.720 |
Why?
| | Monitoring, Physiologic | 4 | 2024 | 267 | 0.720 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2023 | 280 | 0.720 |
Why?
| | Retrospective Studies | 31 | 2025 | 14460 | 0.710 |
Why?
| | Patient Acceptance of Health Care | 5 | 2021 | 764 | 0.700 |
Why?
| | Frailty | 1 | 2023 | 149 | 0.700 |
Why?
| | Patient Positioning | 1 | 2021 | 51 | 0.700 |
Why?
| | Male | 73 | 2025 | 62883 | 0.700 |
Why?
| | Diabetes Insipidus | 1 | 2020 | 7 | 0.690 |
Why?
| | Practice Guidelines as Topic | 6 | 2021 | 1490 | 0.670 |
Why?
| | Substance Withdrawal Syndrome | 3 | 2021 | 171 | 0.640 |
Why?
| | Hospitals, Low-Volume | 1 | 2019 | 22 | 0.630 |
Why?
| | Noninvasive Ventilation | 4 | 2025 | 48 | 0.610 |
Why?
| | Dyspnea | 2 | 2021 | 234 | 0.600 |
Why?
| | Female | 64 | 2025 | 68127 | 0.590 |
Why?
| | Adult | 44 | 2025 | 35315 | 0.570 |
Why?
| | Delirium | 3 | 2025 | 77 | 0.570 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 8 | 2025 | 950 | 0.560 |
Why?
| | Diabetes Mellitus | 2 | 2020 | 1001 | 0.550 |
Why?
| | Alcoholism | 5 | 2021 | 766 | 0.540 |
Why?
| | Ventilator-Induced Lung Injury | 3 | 2018 | 56 | 0.540 |
Why?
| | California | 5 | 2022 | 400 | 0.520 |
Why?
| | Pulmonary Medicine | 3 | 2015 | 80 | 0.520 |
Why?
| | Microbiological Techniques | 1 | 2016 | 30 | 0.520 |
Why?
| | Sleep Medicine Specialty | 1 | 2015 | 9 | 0.500 |
Why?
| | Acute Lung Injury | 6 | 2023 | 264 | 0.500 |
Why?
| | Neoplasms | 3 | 2023 | 2465 | 0.490 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2016 | 97 | 0.480 |
Why?
| | Health Policy | 4 | 2024 | 353 | 0.480 |
Why?
| | Hyperemia | 3 | 2024 | 48 | 0.470 |
Why?
| | Ethanol | 2 | 2021 | 585 | 0.470 |
Why?
| | Randomized Controlled Trials as Topic | 10 | 2023 | 1358 | 0.470 |
Why?
| | Acute Kidney Injury | 7 | 2023 | 774 | 0.450 |
Why?
| | Research Design | 9 | 2023 | 1038 | 0.450 |
Why?
| | Aged, 80 and over | 13 | 2025 | 7040 | 0.450 |
Why?
| | Cohort Studies | 11 | 2023 | 5369 | 0.430 |
Why?
| | Renin-Angiotensin System | 2 | 2025 | 80 | 0.430 |
Why?
| | Prone Position | 3 | 2021 | 30 | 0.430 |
Why?
| | Receptor, EphA2 | 3 | 2018 | 20 | 0.420 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2016 | 626 | 0.420 |
Why?
| | Cause of Death | 3 | 2015 | 391 | 0.410 |
Why?
| | Inpatients | 3 | 2023 | 460 | 0.410 |
Why?
| | Immune Tolerance | 1 | 2015 | 345 | 0.410 |
Why?
| | Laryngoscopes | 2 | 2023 | 35 | 0.410 |
Why?
| | Nicotinic Agonists | 1 | 2014 | 125 | 0.400 |
Why?
| | Dual Specificity Phosphatase 1 | 1 | 2012 | 26 | 0.400 |
Why?
| | Cross Infection | 5 | 2020 | 196 | 0.400 |
Why?
| | Marijuana Smoking | 1 | 2015 | 239 | 0.390 |
Why?
| | Hospitalization | 10 | 2025 | 2071 | 0.390 |
Why?
| | Apoptosis | 6 | 2014 | 2437 | 0.380 |
Why?
| | Lung | 12 | 2018 | 3741 | 0.380 |
Why?
| | Tobacco Use Disorder | 1 | 2014 | 239 | 0.370 |
Why?
| | Nicotine | 1 | 2014 | 303 | 0.370 |
Why?
| | Lipopolysaccharides | 4 | 2017 | 856 | 0.360 |
Why?
| | Organ Dysfunction Scores | 2 | 2024 | 44 | 0.360 |
Why?
| | Pulmonary Fibrosis | 4 | 2017 | 374 | 0.360 |
Why?
| | Tissue Plasminogen Activator | 2 | 2024 | 220 | 0.360 |
Why?
| | Immunity, Innate | 1 | 2017 | 803 | 0.360 |
Why?
| | Protein C | 5 | 2012 | 39 | 0.360 |
Why?
| | Drug Delivery Systems | 1 | 2014 | 326 | 0.360 |
Why?
| | Glycosaminoglycans | 3 | 2016 | 84 | 0.350 |
Why?
| | Prospective Studies | 12 | 2024 | 7043 | 0.350 |
Why?
| | Child Development | 1 | 2015 | 452 | 0.350 |
Why?
| | Long-Term Care | 2 | 2022 | 89 | 0.340 |
Why?
| | Emergency Service, Hospital | 5 | 2024 | 1968 | 0.330 |
Why?
| | Smoking Cessation | 1 | 2014 | 408 | 0.330 |
Why?
| | Antipsychotic Agents | 2 | 2024 | 194 | 0.330 |
Why?
| | Vena Cava, Inferior | 3 | 2024 | 68 | 0.320 |
Why?
| | Comorbidity | 4 | 2022 | 1540 | 0.320 |
Why?
| | Metabolic Syndrome | 2 | 2023 | 340 | 0.320 |
Why?
| | Ephrin-A1 | 3 | 2018 | 4 | 0.320 |
Why?
| | Public Health | 1 | 2014 | 486 | 0.320 |
Why?
| | Treatment Outcome | 15 | 2024 | 10163 | 0.310 |
Why?
| | Length of Stay | 6 | 2024 | 1121 | 0.310 |
Why?
| | United States | 18 | 2024 | 13876 | 0.310 |
Why?
| | Cannabis | 1 | 2015 | 435 | 0.310 |
Why?
| | Lipid A | 2 | 2014 | 29 | 0.300 |
Why?
| | Institutional Practice | 1 | 2008 | 3 | 0.300 |
Why?
| | Intubation, Intratracheal | 4 | 2024 | 241 | 0.300 |
Why?
| | Societies, Medical | 7 | 2021 | 749 | 0.300 |
Why?
| | Biomarkers | 7 | 2023 | 3881 | 0.290 |
Why?
| | Odds Ratio | 6 | 2019 | 1022 | 0.290 |
Why?
| | Betacoronavirus | 2 | 2020 | 249 | 0.290 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2008 | 89 | 0.290 |
Why?
| | Pandemics | 4 | 2024 | 1487 | 0.280 |
Why?
| | Neutrophils | 3 | 2024 | 1188 | 0.280 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1667 | 0.270 |
Why?
| | Pulmonary Alveolar Proteinosis | 1 | 2007 | 17 | 0.270 |
Why?
| | Integrins | 1 | 2007 | 92 | 0.270 |
Why?
| | Neovascularization, Pathologic | 2 | 2007 | 291 | 0.270 |
Why?
| | Haloperidol | 3 | 2025 | 36 | 0.270 |
Why?
| | MAP Kinase Signaling System | 2 | 2014 | 302 | 0.260 |
Why?
| | Patient Admission | 2 | 2023 | 184 | 0.260 |
Why?
| | Hyponatremia | 1 | 2006 | 40 | 0.260 |
Why?
| | Lung Injury | 3 | 2016 | 199 | 0.260 |
Why?
| | Lung Diseases, Obstructive | 1 | 2006 | 44 | 0.260 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2024 | 564 | 0.260 |
Why?
| | Ultrasonography | 3 | 2024 | 723 | 0.250 |
Why?
| | Leukocytes | 1 | 2007 | 303 | 0.250 |
Why?
| | Double-Blind Method | 9 | 2024 | 1860 | 0.250 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 339 | 0.250 |
Why?
| | Coronavirus Infections | 2 | 2020 | 335 | 0.250 |
Why?
| | Medicaid | 3 | 2021 | 437 | 0.250 |
Why?
| | Laryngoscopy | 2 | 2023 | 100 | 0.240 |
Why?
| | Chemokines, CXC | 1 | 2005 | 68 | 0.240 |
Why?
| | Academic Medical Centers | 3 | 2021 | 473 | 0.240 |
Why?
| | Bronchi | 1 | 2006 | 240 | 0.240 |
Why?
| | Biomedical Research | 3 | 2021 | 646 | 0.240 |
Why?
| | Regeneration | 1 | 2006 | 175 | 0.240 |
Why?
| | Oxazines | 1 | 2024 | 26 | 0.240 |
Why?
| | Bronchiolitis Obliterans | 1 | 2005 | 65 | 0.240 |
Why?
| | Bronchiectasis | 1 | 2006 | 110 | 0.230 |
Why?
| | Adrenal Insufficiency | 2 | 2013 | 31 | 0.230 |
Why?
| | Infusions, Intravenous | 5 | 2024 | 384 | 0.230 |
Why?
| | Methylprednisolone | 1 | 2005 | 82 | 0.230 |
Why?
| | Venous Pressure | 1 | 2024 | 9 | 0.230 |
Why?
| | Phagocytosis | 1 | 2006 | 364 | 0.230 |
Why?
| | Patient Protection and Affordable Care Act | 2 | 2016 | 101 | 0.230 |
Why?
| | Plasminogen | 1 | 2024 | 31 | 0.220 |
Why?
| | Morpholines | 1 | 2024 | 125 | 0.220 |
Why?
| | Leukocyte Elastase | 1 | 2024 | 74 | 0.220 |
Why?
| | Anti-Infective Agents | 4 | 2012 | 225 | 0.220 |
Why?
| | Vasopressins | 3 | 2021 | 62 | 0.220 |
Why?
| | Respiratory Mucosa | 1 | 2006 | 305 | 0.220 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2024 | 83 | 0.220 |
Why?
| | Cytokines | 7 | 2017 | 1985 | 0.220 |
Why?
| | beta Catenin | 1 | 2005 | 219 | 0.220 |
Why?
| | Hypoxia | 3 | 2024 | 1031 | 0.220 |
Why?
| | Atrial Pressure | 1 | 2023 | 3 | 0.220 |
Why?
| | Renal Dialysis | 4 | 2023 | 420 | 0.210 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2023 | 21 | 0.210 |
Why?
| | Diterpenes | 2 | 2014 | 32 | 0.210 |
Why?
| | Risk Factors | 10 | 2021 | 9727 | 0.210 |
Why?
| | Area Under Curve | 3 | 2020 | 281 | 0.210 |
Why?
| | Craniocerebral Trauma | 1 | 2005 | 154 | 0.210 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2024 | 122 | 0.210 |
Why?
| | Hemodynamic Monitoring | 1 | 2022 | 1 | 0.210 |
Why?
| | Fibrinolysis | 1 | 2024 | 133 | 0.210 |
Why?
| | Lung Diseases | 3 | 2016 | 722 | 0.200 |
Why?
| | Thiazoles | 2 | 2024 | 115 | 0.200 |
Why?
| | Fibrosis | 1 | 2005 | 522 | 0.200 |
Why?
| | Treatment Failure | 6 | 2021 | 342 | 0.200 |
Why?
| | Evidence-Based Medicine | 5 | 2016 | 717 | 0.190 |
Why?
| | Early Diagnosis | 4 | 2017 | 236 | 0.190 |
Why?
| | Acetaminophen | 1 | 2024 | 249 | 0.190 |
Why?
| | Transportation | 1 | 2022 | 50 | 0.190 |
Why?
| | Clinical Decision-Making | 1 | 2024 | 302 | 0.190 |
Why?
| | Hydrocortisone | 1 | 2003 | 301 | 0.180 |
Why?
| | Pyridines | 1 | 2024 | 469 | 0.180 |
Why?
| | Vasodilator Agents | 1 | 2023 | 321 | 0.180 |
Why?
| | Logistic Models | 7 | 2017 | 1975 | 0.180 |
Why?
| | Central Nervous System Depressants | 1 | 2021 | 83 | 0.180 |
Why?
| | Receptors, Interleukin-6 | 1 | 2021 | 37 | 0.180 |
Why?
| | Heart Arrest | 2 | 2021 | 327 | 0.180 |
Why?
| | Stroke Volume | 1 | 2024 | 588 | 0.180 |
Why?
| | Hospital Charges | 1 | 2020 | 41 | 0.180 |
Why?
| | Piperazines | 2 | 2024 | 334 | 0.180 |
Why?
| | Health Priorities | 1 | 2020 | 34 | 0.170 |
Why?
| | Hydroxychloroquine | 1 | 2020 | 55 | 0.170 |
Why?
| | Rib Fractures | 1 | 2020 | 32 | 0.170 |
Why?
| | Community-Acquired Infections | 3 | 2020 | 152 | 0.170 |
Why?
| | Glucocorticoids | 1 | 2005 | 575 | 0.170 |
Why?
| | Reproducibility of Results | 5 | 2024 | 3023 | 0.170 |
Why?
| | Internship and Residency | 2 | 2019 | 1054 | 0.170 |
Why?
| | Antigens, Differentiation | 1 | 2000 | 82 | 0.170 |
Why?
| | Animals | 20 | 2018 | 34501 | 0.170 |
Why?
| | Heart Failure | 3 | 2023 | 2150 | 0.160 |
Why?
| | Cell Proliferation | 2 | 2014 | 2335 | 0.160 |
Why?
| | Patient Selection | 1 | 2023 | 661 | 0.160 |
Why?
| | Patient Handoff | 1 | 2019 | 31 | 0.160 |
Why?
| | Risk Adjustment | 1 | 2020 | 79 | 0.160 |
Why?
| | Mice, Inbred C57BL | 9 | 2018 | 5257 | 0.160 |
Why?
| | Cell Adhesion Molecules | 1 | 2000 | 172 | 0.160 |
Why?
| | Dopamine Antagonists | 1 | 2018 | 21 | 0.150 |
Why?
| | Hospital Costs | 1 | 2019 | 116 | 0.150 |
Why?
| | Age Factors | 4 | 2019 | 3117 | 0.150 |
Why?
| | Combined Modality Therapy | 2 | 2020 | 1209 | 0.150 |
Why?
| | ROC Curve | 1 | 2020 | 501 | 0.150 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2023 | 599 | 0.150 |
Why?
| | Antimicrobial Stewardship | 1 | 2020 | 99 | 0.150 |
Why?
| | Thrombosis | 1 | 2021 | 321 | 0.150 |
Why?
| | Orthopedic Procedures | 1 | 2020 | 228 | 0.140 |
Why?
| | Caregivers | 1 | 2025 | 807 | 0.140 |
Why?
| | Health Services Accessibility | 4 | 2020 | 892 | 0.140 |
Why?
| | Optometry | 1 | 2017 | 6 | 0.140 |
Why?
| | Platelet Count | 2 | 2014 | 82 | 0.140 |
Why?
| | Eosinophils | 1 | 2000 | 323 | 0.140 |
Why?
| | Guideline Adherence | 2 | 2014 | 525 | 0.140 |
Why?
| | Cell Adhesion | 4 | 2012 | 444 | 0.140 |
Why?
| | Tidal Volume | 2 | 2014 | 83 | 0.140 |
Why?
| | Predictive Value of Tests | 4 | 2016 | 1936 | 0.140 |
Why?
| | Blood Glucose | 2 | 2023 | 2092 | 0.140 |
Why?
| | Lymphocyte Count | 1 | 2017 | 150 | 0.140 |
Why?
| | Analysis of Variance | 1 | 2020 | 1271 | 0.140 |
Why?
| | Transients and Migrants | 1 | 2017 | 24 | 0.140 |
Why?
| | Pyrimidines | 2 | 2024 | 444 | 0.130 |
Why?
| | Tretinoin | 1 | 2017 | 124 | 0.130 |
Why?
| | Mice | 13 | 2017 | 16579 | 0.130 |
Why?
| | Nephrectomy | 2 | 2008 | 159 | 0.130 |
Why?
| | Health Insurance Exchanges | 1 | 2016 | 1 | 0.130 |
Why?
| | Cystic Fibrosis | 1 | 2006 | 1057 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2023 | 892 | 0.130 |
Why?
| | Attitude of Health Personnel | 3 | 2019 | 1090 | 0.130 |
Why?
| | Ventricular Function, Right | 1 | 2018 | 272 | 0.130 |
Why?
| | Continuity of Patient Care | 1 | 2018 | 278 | 0.130 |
Why?
| | Risk Management | 1 | 2017 | 90 | 0.130 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 998 | 0.130 |
Why?
| | Sleep Wake Disorders | 2 | 2017 | 249 | 0.130 |
Why?
| | Breath Tests | 1 | 2016 | 89 | 0.130 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2018 | 224 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 759 | 0.120 |
Why?
| | Burnout, Professional | 1 | 2021 | 408 | 0.120 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 150 | 0.120 |
Why?
| | Research | 1 | 2018 | 409 | 0.120 |
Why?
| | Survival Analysis | 4 | 2014 | 1265 | 0.120 |
Why?
| | Alcohol Withdrawal Seizures | 1 | 2014 | 1 | 0.120 |
Why?
| | Staphylococcus aureus | 2 | 2011 | 425 | 0.120 |
Why?
| | Alcohol Withdrawal Delirium | 1 | 2014 | 7 | 0.120 |
Why?
| | Marriage | 1 | 2016 | 113 | 0.120 |
Why?
| | Bronchoalveolar Lavage | 1 | 2015 | 89 | 0.120 |
Why?
| | Automation | 1 | 2015 | 80 | 0.120 |
Why?
| | 5-Lipoxygenase-Activating Protein Inhibitors | 1 | 2014 | 1 | 0.120 |
Why?
| | 5-Lipoxygenase-Activating Proteins | 1 | 2014 | 2 | 0.120 |
Why?
| | Bacteriological Techniques | 1 | 2015 | 70 | 0.120 |
Why?
| | Prognosis | 5 | 2021 | 3780 | 0.120 |
Why?
| | Multicenter Studies as Topic | 3 | 2023 | 285 | 0.110 |
Why?
| | Risk Assessment | 5 | 2015 | 3256 | 0.110 |
Why?
| | Leukotrienes | 1 | 2014 | 34 | 0.110 |
Why?
| | Patient Care Team | 1 | 2019 | 600 | 0.110 |
Why?
| | Fluorobenzenes | 1 | 2014 | 15 | 0.110 |
Why?
| | Phenanthrenes | 1 | 2014 | 12 | 0.110 |
Why?
| | APACHE | 2 | 2011 | 62 | 0.110 |
Why?
| | Physicians | 2 | 2021 | 860 | 0.110 |
Why?
| | Quality of Life | 2 | 2024 | 2680 | 0.110 |
Why?
| | Education, Medical | 1 | 2017 | 244 | 0.110 |
Why?
| | Catheterization, Central Venous | 1 | 2015 | 97 | 0.110 |
Why?
| | Down-Regulation | 2 | 2017 | 629 | 0.110 |
Why?
| | Potassium | 1 | 2014 | 138 | 0.110 |
Why?
| | Alanine Transaminase | 1 | 2014 | 150 | 0.110 |
Why?
| | Poverty | 2 | 2016 | 494 | 0.110 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2014 | 84 | 0.110 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2000 | 1046 | 0.110 |
Why?
| | Laryngeal Masks | 1 | 2013 | 10 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 5 | 2018 | 857 | 0.110 |
Why?
| | Microscopy | 1 | 2015 | 140 | 0.110 |
Why?
| | Quinolines | 1 | 2014 | 149 | 0.110 |
Why?
| | Time Factors | 7 | 2023 | 6503 | 0.100 |
Why?
| | Glycocalyx | 1 | 2012 | 19 | 0.100 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2024 | 1271 | 0.100 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 1820 | 0.100 |
Why?
| | Patient-Centered Care | 1 | 2017 | 493 | 0.100 |
Why?
| | Patient Discharge | 1 | 2018 | 849 | 0.100 |
Why?
| | Cisplatin | 1 | 2014 | 297 | 0.100 |
Why?
| | Supine Position | 1 | 2012 | 38 | 0.100 |
Why?
| | Physician-Patient Relations | 1 | 2017 | 530 | 0.100 |
Why?
| | Acute Disease | 3 | 2016 | 968 | 0.100 |
Why?
| | Biomarkers, Pharmacological | 1 | 2012 | 26 | 0.100 |
Why?
| | Data Interpretation, Statistical | 2 | 2011 | 335 | 0.100 |
Why?
| | Oxygen | 3 | 2023 | 901 | 0.100 |
Why?
| | I-kappa B Proteins | 1 | 2012 | 73 | 0.100 |
Why?
| | Clinical Alarms | 1 | 2011 | 10 | 0.100 |
Why?
| | Data Display | 1 | 2011 | 20 | 0.100 |
Why?
| | Insurance, Health | 1 | 2014 | 271 | 0.090 |
Why?
| | Health Status | 1 | 2017 | 751 | 0.090 |
Why?
| | Endotoxemia | 1 | 2012 | 83 | 0.090 |
Why?
| | Follow-Up Studies | 5 | 2024 | 4898 | 0.090 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2011 | 35 | 0.090 |
Why?
| | Indoles | 1 | 2014 | 367 | 0.090 |
Why?
| | Albuterol | 1 | 2011 | 104 | 0.090 |
Why?
| | Genetic Markers | 1 | 2012 | 339 | 0.090 |
Why?
| | Fibrinolytic Agents | 2 | 2024 | 249 | 0.090 |
Why?
| | Sulfonamides | 1 | 2014 | 500 | 0.090 |
Why?
| | Alcohol-Related Disorders | 1 | 2011 | 115 | 0.090 |
Why?
| | Peroxidase | 2 | 2008 | 169 | 0.080 |
Why?
| | Stenotrophomonas maltophilia | 1 | 2009 | 2 | 0.080 |
Why?
| | Recombinant Proteins | 5 | 2012 | 1284 | 0.080 |
Why?
| | Thoracic Diseases | 1 | 2009 | 14 | 0.080 |
Why?
| | Decision Making | 1 | 2017 | 850 | 0.080 |
Why?
| | Clinical Protocols | 2 | 2012 | 253 | 0.080 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 411 | 0.080 |
Why?
| | Interferons | 1 | 2011 | 192 | 0.080 |
Why?
| | Survival Rate | 3 | 2015 | 1872 | 0.080 |
Why?
| | Adrenal Cortex Hormones | 1 | 2013 | 518 | 0.080 |
Why?
| | Ligands | 2 | 2023 | 614 | 0.080 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2009 | 43 | 0.080 |
Why?
| | Symptom Assessment | 2 | 2020 | 125 | 0.080 |
Why?
| | Blotting, Western | 1 | 2012 | 1168 | 0.080 |
Why?
| | Wounds and Injuries | 1 | 2016 | 714 | 0.080 |
Why?
| | Cell Movement | 3 | 2011 | 937 | 0.080 |
Why?
| | Disease Models, Animal | 5 | 2018 | 3943 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1019 | 0.080 |
Why?
| | Databases, Factual | 2 | 2016 | 1268 | 0.080 |
Why?
| | Confidence Intervals | 1 | 2010 | 318 | 0.080 |
Why?
| | Up-Regulation | 1 | 2012 | 826 | 0.080 |
Why?
| | Cues | 1 | 2011 | 319 | 0.080 |
Why?
| | Age Distribution | 1 | 2010 | 376 | 0.080 |
Why?
| | Sex Distribution | 1 | 2010 | 359 | 0.080 |
Why?
| | Pneumonia, Bacterial | 1 | 2009 | 109 | 0.080 |
Why?
| | Pancreatitis | 1 | 2009 | 128 | 0.080 |
Why?
| | Pulmonary Alveoli | 2 | 2012 | 366 | 0.080 |
Why?
| | Work Schedule Tolerance | 1 | 2008 | 42 | 0.070 |
Why?
| | Models, Statistical | 1 | 2012 | 625 | 0.070 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2023 | 90 | 0.070 |
Why?
| | Healthcare Disparities | 1 | 2014 | 576 | 0.070 |
Why?
| | Incidence | 1 | 2014 | 2619 | 0.070 |
Why?
| | United Kingdom | 1 | 2008 | 256 | 0.070 |
Why?
| | Pulmonary Emphysema | 2 | 2007 | 244 | 0.070 |
Why?
| | Interleukin-6 | 2 | 2008 | 716 | 0.070 |
Why?
| | Mandatory Programs | 1 | 2007 | 14 | 0.070 |
Why?
| | Child, Preschool | 2 | 2015 | 10373 | 0.070 |
Why?
| | Flavonoids | 1 | 2007 | 77 | 0.070 |
Why?
| | Demeclocycline | 1 | 2006 | 3 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 1 | 2012 | 2245 | 0.070 |
Why?
| | Clinical Competence | 1 | 2014 | 1014 | 0.070 |
Why?
| | Mice, Inbred C3H | 1 | 2007 | 274 | 0.070 |
Why?
| | Disease Progression | 4 | 2017 | 2603 | 0.070 |
Why?
| | Methicillin Resistance | 1 | 2006 | 17 | 0.070 |
Why?
| | Lithium Compounds | 1 | 2006 | 12 | 0.070 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2007 | 148 | 0.070 |
Why?
| | Signal Transduction | 4 | 2018 | 4829 | 0.070 |
Why?
| | Workload | 1 | 2008 | 150 | 0.070 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 1995 | 1044 | 0.070 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2007 | 179 | 0.070 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2012 | 132 | 0.070 |
Why?
| | Diuretics | 1 | 2006 | 74 | 0.060 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2006 | 99 | 0.060 |
Why?
| | Hospitals, Urban | 2 | 2018 | 134 | 0.060 |
Why?
| | Hospital Information Systems | 1 | 2006 | 14 | 0.060 |
Why?
| | Mesoderm | 1 | 2007 | 136 | 0.060 |
Why?
| | Sex Factors | 3 | 2018 | 1949 | 0.060 |
Why?
| | Rats | 2 | 2012 | 5168 | 0.060 |
Why?
| | History, 20th Century | 2 | 2017 | 291 | 0.060 |
Why?
| | Radiography, Thoracic | 1 | 2007 | 163 | 0.060 |
Why?
| | Adolescent | 5 | 2025 | 20213 | 0.060 |
Why?
| | Asparagine | 1 | 2005 | 28 | 0.060 |
Why?
| | Hypertension, Pulmonary | 2 | 2007 | 1735 | 0.060 |
Why?
| | Butylated Hydroxytoluene | 1 | 2005 | 38 | 0.060 |
Why?
| | Mice, Inbred BALB C | 2 | 2005 | 1229 | 0.060 |
Why?
| | Emphysema | 1 | 2006 | 95 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 2 | 2024 | 872 | 0.060 |
Why?
| | Cyclin D1 | 1 | 2005 | 63 | 0.060 |
Why?
| | Vocabulary | 1 | 2006 | 46 | 0.060 |
Why?
| | Heparin | 1 | 2007 | 240 | 0.060 |
Why?
| | Bronchoscopy | 1 | 2007 | 208 | 0.060 |
Why?
| | Cell Line, Transformed | 1 | 2005 | 140 | 0.060 |
Why?
| | Medical Order Entry Systems | 1 | 2006 | 43 | 0.060 |
Why?
| | Caspase Inhibitors | 1 | 2005 | 77 | 0.060 |
Why?
| | Young Adult | 5 | 2025 | 12320 | 0.060 |
Why?
| | Venous Thrombosis | 1 | 2007 | 158 | 0.060 |
Why?
| | Occupational Health | 1 | 2008 | 195 | 0.060 |
Why?
| | Blood Vessels | 1 | 2007 | 184 | 0.060 |
Why?
| | Gene Expression Regulation | 2 | 2012 | 2506 | 0.060 |
Why?
| | Angiotensin I | 1 | 2025 | 7 | 0.060 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1687 | 0.060 |
Why?
| | Ischemia | 1 | 2008 | 395 | 0.060 |
Why?
| | Androstanols | 1 | 2024 | 9 | 0.060 |
Why?
| | Neuromuscular Nondepolarizing Agents | 1 | 2024 | 12 | 0.060 |
Why?
| | Necrosis | 1 | 2005 | 231 | 0.060 |
Why?
| | HMGB1 Protein | 1 | 2005 | 48 | 0.060 |
Why?
| | Pyridazines | 1 | 2024 | 50 | 0.060 |
Why?
| | Caspases | 1 | 2005 | 242 | 0.060 |
Why?
| | Hope | 1 | 2024 | 22 | 0.060 |
Why?
| | Macrophages | 2 | 2014 | 1463 | 0.060 |
Why?
| | Colorado | 4 | 2017 | 4392 | 0.060 |
Why?
| | Medicago | 1 | 2023 | 1 | 0.060 |
Why?
| | Cadherins | 1 | 2005 | 186 | 0.060 |
Why?
| | T-Lymphocyte Subsets | 1 | 2006 | 410 | 0.060 |
Why?
| | Diabetic Ketoacidosis | 1 | 2007 | 198 | 0.060 |
Why?
| | Renal Replacement Therapy | 1 | 2024 | 84 | 0.060 |
Why?
| | Steroids | 2 | 2021 | 148 | 0.060 |
Why?
| | Uncertainty | 1 | 2024 | 114 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 3 | 2024 | 1266 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 811 | 0.050 |
Why?
| | Atrial Function, Right | 1 | 2023 | 11 | 0.050 |
Why?
| | Angiotensins | 1 | 2023 | 9 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1494 | 0.050 |
Why?
| | Heparitin Sulfate | 2 | 2014 | 41 | 0.050 |
Why?
| | Collagen | 1 | 2005 | 429 | 0.050 |
Why?
| | Mental Health | 2 | 2022 | 684 | 0.050 |
Why?
| | Drug Administration Schedule | 2 | 2018 | 757 | 0.050 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2007 | 312 | 0.050 |
Why?
| | Biopsy | 1 | 2007 | 1085 | 0.050 |
Why?
| | Autoimmune Diseases | 1 | 2006 | 423 | 0.050 |
Why?
| | Homeostasis | 1 | 2006 | 605 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 2058 | 0.050 |
Why?
| | Angiotensin II | 1 | 2023 | 93 | 0.050 |
Why?
| | Decision Support Techniques | 2 | 2020 | 398 | 0.050 |
Why?
| | Anticoagulants | 1 | 2007 | 613 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1416 | 0.050 |
Why?
| | Video Recording | 1 | 2023 | 164 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 1995 | 2323 | 0.050 |
Why?
| | Hemoglobins | 1 | 2024 | 336 | 0.050 |
Why?
| | Child | 2 | 2015 | 20721 | 0.050 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2014 | 269 | 0.050 |
Why?
| | Staphylococcal Infections | 1 | 2006 | 380 | 0.050 |
Why?
| | Endothelial Cells | 1 | 2007 | 701 | 0.050 |
Why?
| | Partial Thromboplastin Time | 1 | 2021 | 49 | 0.050 |
Why?
| | Creatinine | 2 | 2015 | 475 | 0.050 |
Why?
| | Infant | 1 | 2015 | 8913 | 0.050 |
Why?
| | Oligopeptides | 1 | 2023 | 257 | 0.050 |
Why?
| | Perioperative Care | 1 | 2022 | 149 | 0.050 |
Why?
| | Electrocardiography | 1 | 2024 | 607 | 0.040 |
Why?
| | Antibodies | 2 | 2018 | 391 | 0.040 |
Why?
| | Peptide Fragments | 1 | 2025 | 685 | 0.040 |
Why?
| | Lung Diseases, Interstitial | 1 | 2007 | 592 | 0.040 |
Why?
| | Hemorrhage | 1 | 2005 | 644 | 0.040 |
Why?
| | Leukotriene C4 | 1 | 2000 | 11 | 0.040 |
Why?
| | CD18 Antigens | 1 | 2000 | 26 | 0.040 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 1 | 2000 | 54 | 0.040 |
Why?
| | Drug Resistance, Microbial | 1 | 2020 | 63 | 0.040 |
Why?
| | Chronic Disease | 1 | 2006 | 1701 | 0.040 |
Why?
| | CD11 Antigens | 1 | 2000 | 29 | 0.040 |
Why?
| | Glasgow Coma Scale | 1 | 2020 | 170 | 0.040 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 208 | 0.040 |
Why?
| | Epithelial Cells | 1 | 2005 | 1036 | 0.040 |
Why?
| | Smoking | 1 | 2006 | 1463 | 0.040 |
Why?
| | Hospitals, University | 1 | 2019 | 175 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2017 | 1141 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2005 | 1188 | 0.040 |
Why?
| | Needs Assessment | 1 | 2021 | 360 | 0.040 |
Why?
| | Aftercare | 1 | 2001 | 205 | 0.040 |
Why?
| | NF-kappa B | 2 | 2018 | 651 | 0.040 |
Why?
| | Infection Control | 1 | 2020 | 133 | 0.040 |
Why?
| | Surveys and Questionnaires | 3 | 2021 | 5346 | 0.040 |
Why?
| | Algorithms | 1 | 2006 | 1616 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2000 | 221 | 0.040 |
Why?
| | Injury Severity Score | 1 | 2020 | 511 | 0.040 |
Why?
| | Class Ib Phosphatidylinositol 3-Kinase | 1 | 2018 | 4 | 0.040 |
Why?
| | Mice, Knockout | 3 | 2012 | 2752 | 0.040 |
Why?
| | Linear Models | 1 | 2020 | 816 | 0.040 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2018 | 34 | 0.040 |
Why?
| | T-Lymphocytes | 1 | 2006 | 1922 | 0.040 |
Why?
| | Trauma Centers | 1 | 2020 | 403 | 0.040 |
Why?
| | Victoria | 1 | 2017 | 16 | 0.040 |
Why?
| | Mortality | 1 | 2019 | 307 | 0.040 |
Why?
| | Antigens, CD | 1 | 2000 | 479 | 0.040 |
Why?
| | Family | 1 | 2022 | 642 | 0.040 |
Why?
| | History, 17th Century | 1 | 2017 | 14 | 0.030 |
Why?
| | History, 16th Century | 1 | 2017 | 14 | 0.030 |
Why?
| | History, 15th Century | 1 | 2017 | 11 | 0.030 |
Why?
| | United Arab Emirates | 1 | 2017 | 7 | 0.030 |
Why?
| | History, Ancient | 1 | 2017 | 52 | 0.030 |
Why?
| | History, Medieval | 1 | 2017 | 44 | 0.030 |
Why?
| | Drug Therapy, Combination | 2 | 2012 | 1009 | 0.030 |
Why?
| | Critical Care Outcomes | 1 | 2016 | 12 | 0.030 |
Why?
| | Recovery of Function | 1 | 2021 | 643 | 0.030 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2025 | 832 | 0.030 |
Why?
| | History, 21st Century | 1 | 2017 | 180 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5040 | 0.030 |
Why?
| | Trauma Severity Indices | 1 | 2016 | 106 | 0.030 |
Why?
| | Probability | 1 | 2017 | 308 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2000 | 1098 | 0.030 |
Why?
| | Refugees | 1 | 2017 | 65 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2018 | 421 | 0.030 |
Why?
| | Anxiety | 1 | 2022 | 949 | 0.030 |
Why?
| | Uteroglobin | 1 | 2014 | 21 | 0.030 |
Why?
| | Chemokine CXCL2 | 1 | 2014 | 43 | 0.030 |
Why?
| | Pilot Projects | 1 | 2019 | 1558 | 0.030 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2014 | 38 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 581 | 0.030 |
Why?
| | Rosuvastatin Calcium | 1 | 2014 | 20 | 0.030 |
Why?
| | Nitrites | 1 | 2014 | 81 | 0.030 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2014 | 28 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2018 | 1197 | 0.030 |
Why?
| | Risk | 1 | 2017 | 852 | 0.030 |
Why?
| | Creatine Kinase | 1 | 2014 | 75 | 0.030 |
Why?
| | Epoxy Compounds | 1 | 2014 | 32 | 0.030 |
Why?
| | Nitrates | 1 | 2014 | 87 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2017 | 296 | 0.030 |
Why?
| | Chondroitin Sulfates | 1 | 2014 | 34 | 0.030 |
Why?
| | Toll-Like Receptor 2 | 1 | 2014 | 110 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2014 | 145 | 0.030 |
Why?
| | Manikins | 1 | 2013 | 23 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2014 | 327 | 0.030 |
Why?
| | Liver Failure | 1 | 2014 | 90 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2015 | 374 | 0.030 |
Why?
| | Bronchial Spasm | 1 | 2013 | 6 | 0.030 |
Why?
| | Cryptogenic Organizing Pneumonia | 1 | 2013 | 17 | 0.030 |
Why?
| | Quality Improvement | 1 | 2021 | 1100 | 0.030 |
Why?
| | Contraindications | 1 | 2013 | 88 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2016 | 660 | 0.030 |
Why?
| | Depression | 1 | 2022 | 1289 | 0.030 |
Why?
| | Anesthesiology | 1 | 2013 | 45 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2015 | 450 | 0.030 |
Why?
| | Glucuronidase | 1 | 2012 | 42 | 0.030 |
Why?
| | Protein C Deficiency | 1 | 2012 | 2 | 0.030 |
Why?
| | Connective Tissue Diseases | 1 | 2013 | 81 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2012 | 82 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2000 | 4008 | 0.020 |
Why?
| | Knowledge Bases | 1 | 2012 | 22 | 0.020 |
Why?
| | Intestinal Perforation | 1 | 2012 | 44 | 0.020 |
Why?
| | Toll-Like Receptor 4 | 1 | 2014 | 263 | 0.020 |
Why?
| | Renal Insufficiency | 1 | 2014 | 148 | 0.020 |
Why?
| | Triage | 1 | 2014 | 211 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2017 | 607 | 0.020 |
Why?
| | Endothelium | 1 | 2012 | 106 | 0.020 |
Why?
| | Water-Electrolyte Balance | 1 | 2011 | 35 | 0.020 |
Why?
| | Disease Management | 1 | 2016 | 588 | 0.020 |
Why?
| | Quality Assurance, Health Care | 1 | 2014 | 316 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2012 | 216 | 0.020 |
Why?
| | Epistasis, Genetic | 1 | 2012 | 71 | 0.020 |
Why?
| | General Surgery | 1 | 2013 | 157 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2013 | 513 | 0.020 |
Why?
| | Cell Survival | 1 | 2014 | 1077 | 0.020 |
Why?
| | Microbial Viability | 1 | 2011 | 83 | 0.020 |
Why?
| | Superoxides | 1 | 2011 | 196 | 0.020 |
Why?
| | Internal Medicine | 1 | 2013 | 246 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2012 | 799 | 0.020 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2014 | 278 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2011 | 258 | 0.020 |
Why?
| | Viruses | 1 | 2011 | 99 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2697 | 0.020 |
Why?
| | Cell Separation | 1 | 2011 | 313 | 0.020 |
Why?
| | Single-Payer System | 1 | 2009 | 2 | 0.020 |
Why?
| | Species Specificity | 1 | 2011 | 567 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2011 | 656 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2011 | 664 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 348 | 0.020 |
Why?
| | Survivors | 1 | 2013 | 461 | 0.020 |
Why?
| | Information Dissemination | 1 | 2011 | 204 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 814 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2014 | 886 | 0.020 |
Why?
| | Advisory Committees | 1 | 2010 | 219 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2016 | 3326 | 0.020 |
Why?
| | Drug Resistance, Bacterial | 1 | 2009 | 173 | 0.020 |
Why?
| | Self Report | 1 | 2013 | 801 | 0.020 |
Why?
| | Cell Line | 1 | 2014 | 2731 | 0.020 |
Why?
| | Total Quality Management | 1 | 2008 | 60 | 0.020 |
Why?
| | Ventilator Weaning | 1 | 2008 | 35 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2009 | 335 | 0.020 |
Why?
| | Precision Medicine | 1 | 2012 | 383 | 0.020 |
Why?
| | Placebos | 1 | 2008 | 201 | 0.020 |
Why?
| | Neutrophil Infiltration | 1 | 2008 | 97 | 0.020 |
Why?
| | Capillary Permeability | 1 | 2008 | 131 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2008 | 198 | 0.020 |
Why?
| | Health Plan Implementation | 1 | 2008 | 136 | 0.020 |
Why?
| | Interdisciplinary Communication | 1 | 2008 | 187 | 0.020 |
Why?
| | Drug Industry | 1 | 2008 | 106 | 0.020 |
Why?
| | Chemokines | 1 | 2008 | 221 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2012 | 1190 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 1943 | 0.020 |
Why?
| | Acid-Base Equilibrium | 1 | 2007 | 27 | 0.020 |
Why?
| | Cost Control | 1 | 2006 | 38 | 0.020 |
Why?
| | Umbilical Veins | 1 | 2006 | 58 | 0.020 |
Why?
| | Microcirculation | 1 | 2007 | 137 | 0.020 |
Why?
| | Medical Audit | 1 | 2007 | 76 | 0.020 |
Why?
| | CD8 Antigens | 1 | 2006 | 75 | 0.020 |
Why?
| | Ketones | 1 | 2007 | 47 | 0.020 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 89 | 0.020 |
Why?
| | CD4 Antigens | 1 | 2006 | 137 | 0.020 |
Why?
| | Bacillus subtilis | 1 | 2006 | 65 | 0.020 |
Why?
| | Information Management | 1 | 2006 | 15 | 0.020 |
Why?
| | Cell Count | 1 | 2006 | 314 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2006 | 374 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2012 | 1337 | 0.010 |
Why?
| | User-Computer Interface | 1 | 2006 | 148 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2006 | 299 | 0.010 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2007 | 255 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 2065 | 0.010 |
Why?
| | Inflammation Mediators | 1 | 2006 | 500 | 0.010 |
Why?
| | Asthma | 1 | 2017 | 2215 | 0.010 |
Why?
| | Hypoglycemia | 1 | 2007 | 426 | 0.010 |
Why?
| | Cardiotonic Agents | 1 | 2001 | 124 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 2007 | 871 | 0.010 |
Why?
| | Hypothermia, Induced | 1 | 2001 | 73 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2006 | 2674 | 0.010 |
Why?
| | Mass Screening | 1 | 2006 | 1152 | 0.010 |
Why?
| | Dopamine | 1 | 2001 | 285 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2007 | 1214 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 2001 | 469 | 0.010 |
Why?
| | Insulin | 1 | 2007 | 2318 | 0.010 |
Why?
|
|
Douglas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|